Edition:
India

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

5.80USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$5.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,377
52-wk High
$96.25
52-wk Low
$5.80

Select another date:

Tue, May 8 2018

BRIEF-Invivo Therapeutics Reports Q1 Loss Per Share Of $3.34

* INVIVO THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

BRIEF-Invivo Therapeutics Files For Offering Of Up To $8 Mln Shares

* INVIVO THERAPEUTICS HOLDINGS CORP FILES FOR OFFERING OF UP TO $8 MILLION SHARES OF COMMON STOCK, WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING Source text (https://bit.ly/2HrYEIM) Further company coverage:

BRIEF-Invivo Therapeutics Announces Reverse Stock Split

* ANTICIPATES REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 5:00 P.M. EASTERN TIME ON APRIL 16, 2018

BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™

* INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-InVivo Therapeutics Appoints Richard Toselli As Chief Executive Officer

* INVIVO THERAPEUTICS ANNOUNCES APPOINTMENT OF RICHARD TOSELLI, M.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRIEF-Invivo Therapeutics Says There Is Substantial Doubt About Ability To Continue As A Going Concern

* INVIVO THERAPEUTICS SAYS "THERE IS SUBSTANTIAL DOUBT ABOUT OUR ABILITY TO CONTINUE AS A GOING CONCERN" - SEC FILING

BRIEF-Invivo Therapeutics Announces Purchase Agreement For Up To $15 Mln With Lincoln Park Capital

* INVIVO THERAPEUTICS ANNOUNCES PURCHASE AGREEMENT FOR UP TO $15 MILLION WITH LINCOLN PARK CAPITAL

BRIEF-InVivo Therapeutics Announces Latest Results From INSPIRE

* INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD

InVivo to open crop input unit to outside investors

PARIS, Dec 19 French agricultural group InVivo said on Tuesday that it plans to raise 50 million euros ($59 million) for its Bioline division, which develops crop inputs such as seeds and pesticides, by bringing in outside investors.

BRIEF-InVivo Therapeutics Announces Executive Management And Board Changes

* INVIVO THERAPEUTICS ANNOUNCES EXECUTIVE MANAGEMENT AND BOARD CHANGES

Select another date: